Synapse - Find an Expert

5608 Results

ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Maneval, E. C.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy

Meeting Abstract

Rathkopf, D. E.; Smith, M. R.; De Bono, J. S.; Logothetis, C.; Shore, N. D.; De Souza, P. L.; Fizazi, K.; Mulders, P.; Mainwaring, P. N.; Hainsworth, J. D.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride

Meeting Abstract

Robinson, M. O.; Feng, B.; Nicoletti, R.; Berkenblit, A.; Strahs, A. L.; Esteves, B.; Eisen, T.; Motzer, R. J.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor

Meeting Abstract

Scher, H. I.; Fizazi, K.; Saad, F.; Chi, K. N.; Taplin, M. E.; Sternberg, C. N.; Armstrong, A. J.; Hirmand, M.; Forer, D.; De Bono, J. S.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Prognostic value of serum and rogens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data

Meeting Abstract

Ryan, C. J.; Molina, A.; Li, J.; Kheoh, T. S.; Small, E. J.; Haqq, C. M.; Grant, R. P.; De Bono, J. S.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)

Meeting Abstract

Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2